In the strong-performing health care sector, I could have done a much better job with surging biotechnology stocks, notable mistakes included not owning enough Amgen, a biotech firm that made excellent advances, and avoiding index stock Allergan, the specialty drug company that announced plans to be acquired by Actavis.